SCHEMBL2408765

SCHEMBL2408765

CC(C)(C)C(NC(=O)c1cnccn1)c1ccc(C(=O)NO)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
HTT P42858 1/20 0.47
KDM4E B2RXH2 2/20 0.46
PDE2A O00408 3/20 0.44
HDAC1 Q13547 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
HDAC8 Q9BY41 1/20 0.43
LONP1 P36776 1/20 0.43
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
GAA P10253 1/20 0.41
RECQL P46063 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2407967 0.84 HDAC1 (0.58) SMN1; SMN2HTTKDM4EPDE2AHDAC1
SCHEMBL2407595 0.81 HDAC1 (0.43) PDE2AHDAC1HDAC6HDAC8
SCHEMBL2407569 0.77 TLR7 (0.49) KDM4EPDE2AHDAC1HDAC6HDAC8
SCHEMBL12279807 0.76 HDAC6 (0.61) SMN1; SMN2PDE2AHDAC1HDAC6HDAC8
SCHEMBL2409463 0.76 HDAC1 (0.67) SMN1; SMN2HDAC1HDAC6HDAC8
SCHEMBL2406750 0.76 HDAC1 (0.47) SMN1; SMN2PDE2AHDAC1HDAC6HDAC8
SCHEMBL12279790 0.75 PDE2A (0.47) PDE2AHDAC1HDAC6HDAC8GAA
SCHEMBL12280557 0.74 HDAC6 (0.54) HDAC1HDAC6HDAC8
SCHEMBL8293294 0.74 KDM4E (0.58) SMN1; SMN2HTTKDM4ELONP1NPC1
SCHEMBL2407846 0.74 PDE2A (0.54) PDE2AHDAC1HDAC6HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US claimed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
WO-2011106632-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 WO disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 SMN1; SMN2 975/4885HTT 97/4885KDM4E 875/4885
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 SMN1; SMN2 975/4885HTT 97/4885KDM4E 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.